Electronic Decision support for Improvement of Contemporary Therapy for Stroke Prevention.

BACKGROUND Despite ample clinical trial data demonstrating that oral anticoagulation (OAC) treatment is highly effective in reducing stroke for patients with atrial fibrillation (AF), OAC treatment remains underutilized in current clinical practice. Targeting hospitalist and emergency department providers with electronic decision support represents a potential quality improvement opportunity in the use of OAC medication in AF patients. METHODS We conducted a 3-center study in which 2 sites utilized an electronic alert (EA) embedded in the electronic health record and 1 site provided usual care. The EA calculated the CHA2DS2-VASc score for clinicians. Patients were tracked following discharge from either the emergency department or hospital. We hypothesized that the EA would increase the rate of OAC use by 15% compared to usual care, with a study sample size of 360 patients. Study exclusions included severe heart valve disease, advanced renal disease, and severe dementia. The primary endpoint was OAC use at the time of hospital discharge or 30 days after hospital discharge (whichever was the last observation recorded). RESULTS Among 309 patients included for analysis (mean age 70.2 years), the median CHA2DS2-VASc score was 3.5. The frequency of OAC use at follow-up at the usual care hospital was 55.9% (95% confidence interval 47.4-67.9). At the 2 EA sites, the rate of OAC use at the last observation point was 43.9% (P = .06). Aspirin use at follow-up was similar at the usual care site and the EA sites (53.8% versus 46.3%). The rate of OAC use in patients greater than 75 years was 60.0% in the usual care site and 48.4% (P = .09) at the EA sites. CONCLUSIONS The EA in our study was not sufficient to ameliorate therapeutic inertia in the use of OAC for stroke prevention in AF.

[1]  G. Breithardt,et al.  Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. , 2011, The New England journal of medicine.

[2]  M. Fornage,et al.  Guidelines for the Primary Prevention of Stroke: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association , 2011, Stroke.

[3]  K. Furie,et al.  Admission international normalized ratio and acute infarct volume in ischemic stroke , 2008, Annals of neurology.

[4]  Stephen S. Cha,et al.  Secular Trends in Incidence of Atrial Fibrillation in Olmsted County, Minnesota, 1980 to 2000, and Implications on the Projections for Future Prevalence , 2006, Circulation.

[5]  G. Saposnik,et al.  Aversion to ambiguity and willingness to take risks affect therapeutic decisions in managing atrial fibrillation for stroke prevention: results of a pilot study in family physicians , 2017, Patient preference and adherence.

[6]  G. Lip,et al.  Underuse of oral anticoagulants in atrial fibrillation: a systematic review. , 2010, The American journal of medicine.

[7]  S. Yusuf,et al.  Dabigatran versus warfarin in patients with atrial fibrillation. , 2009, The New England journal of medicine.

[8]  P. Caraballo,et al.  An Automated Clinical Alert System for Newly-Diagnosed Atrial Fibrillation , 2015, PloS one.

[9]  C. Kase,et al.  Summary of evidence-based guideline update: Prevention of stroke in nonvalvular atrial fibrillation , 2014, Neurology.

[10]  D. Atar,et al.  Apixaban versus warfarin in patients with atrial fibrillation. , 2011, The New England journal of medicine.

[11]  B. Gage,et al.  Use and Effectiveness of Warfarin in Medicare Beneficiaries With Atrial Fibrillation , 2006, Stroke.

[12]  Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice? , 2003 .

[13]  H. Mcdonald,et al.  Effects of computerized clinical decision support systems on practitioner performance and patient outcomes: a systematic review. , 2005, JAMA.

[14]  David J. Gladstone,et al.  Potentially Preventable Strokes in High-Risk Patients With Atrial Fibrillation Who Are Not Adequately Anticoagulated , 2009, Stroke.

[15]  M. Aguilar,et al.  Meta-analysis: Antithrombotic Therapy to Prevent Stroke in Patients Who Have Nonvalvular Atrial Fibrillation , 2007, Annals of Internal Medicine.

[16]  F. McAlister,et al.  Why do patients with atrial fibrillation not receive warfarin? , 2000, Archives of internal medicine.

[17]  C. Granger,et al.  Newer Oral Anticoagulants Should Be Used as First-Line Agents to Prevent Thromboembolism in Patients With Atrial Fibrillation and Risk Factors for Stroke or Thromboembolism , 2012, Circulation.

[18]  S. Dovey,et al.  Cluster randomized controlled trial of TIA electronic decision support in primary care , 2015, Neurology.

[19]  L. Sposato,et al.  Therapeutic Decisions in Atrial Fibrillation for Stroke Prevention: The Role of Aversion to Ambiguity and Physicians' Risk Preferences. , 2018, Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association.

[20]  Marilyn D. Paterno,et al.  Electronic alerts to prevent venous thromboembolism among hospitalized patients , 2005 .

[21]  Michael J Pencina,et al.  Association of Preceding Antithrombotic Treatment With Acute Ischemic Stroke Severity and In-Hospital Outcomes Among Patients With Atrial Fibrillation , 2017, JAMA.

[22]  Nils Kucher,et al.  Electronic Alert System for Improving Stroke Prevention Among Hospitalized Oral‐Anticoagulation‐Naïve Patients With Atrial Fibrillation: A Randomized Trial , 2016, Journal of the American Heart Association.

[23]  Salim Yusuf,et al.  Effect of clopidogrel added to aspirin in patients with atrial fibrillation. , 2009, The New England journal of medicine.

[24]  Karen L. Furie,et al.  Stroke Associated with Atrial Fibrillation – Incidence and Early Outcomes in the North Dublin Population Stroke Study , 2009, Cerebrovascular Diseases.

[25]  D. Fitzmaurice,et al.  Automated Software System to Promote Anticoagulation and Reduce Stroke Risk: Cluster-Randomized Controlled Trial , 2017, Stroke.